Abbvie (DE:4AB)
NYSE:4AB
4AB Stock Chart & Stats
€178.65
-€0.44(-0.25%)
At close: 4:00 PM EST
€178.65
-€0.44(-0.25%)
Day’s Range― - ―
52-Week Range€155.20 - €207.00
Previous CloseN/A
Volume1.25K
Average Volume (3M)430.00
Market Cap
€355.60B
Enterprise Value€454.33B
Total Cash (Recent Filing)€9.39B
Total Debt (Recent Filing)€72.86B
Price to Earnings (P/E)112.8
Beta0.28
Next Earnings
Jul 24, 2026EPS Estimate
3.29Next Dividend Ex-DateN/A
Dividend Yield2.93%
Share Statistics
EPS (TTM)2.04
Shares Outstanding1,766,792,800
10 Day Avg. Volume336
30 Day Avg. Volume430
Financial Highlights & Ratios
PEG Ratio-77.13
Price to Book (P/B)-124.40
Price to Sales (P/S)6.65
P/FCF Ratio22.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€226.01Price Target Upside26.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)12.45
Revenue Forecast (FY)€58.91B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow StrengthConsistent, sizable free cash flow provides durable flexibility for R&D, manufacturing buildouts, dividends and opportunistic M&A. With FCF roughly tracking net income and growing, AbbVie can fund pipeline investment and shareholder returns even as revenue mix shifts, supporting long-term strategic options.
Immunology Commercial MomentumRapid growth of Skyrizi and Rinvoq reflects durable market share gains across psoriasis, IBD and related indications, reducing reliance on legacy Humira sales. Multi-indication traction and high percent growth support sustainable revenue base and lifecycle extension through label expansion and combination programs.
Pipeline & Strategic BD (Apogee)Acquiring Apogee meaningfully deepens AbbVie's immunology and respiratory pipeline with late-stage IL‑13 and combo programs, diversifying growth drivers beyond current franchises. This structural pipeline build strengthens long-term product flow and reduces single-product concentration risk.
Bears Say
High LeverageSubstantial absolute debt and elevated leverage limit financial flexibility, increase interest burden and heighten refinancing risk if earnings falter. Negative/volatile equity signals capital structure strain and can constrain strategic moves or require slower capital returns under adverse operating scenarios.
HUMIRA Biosimilar ErosionRapid Humira revenue decline from biosimilar competition is a structural revenue headwind, forcing the company to replace a formerly massive cash engine. Transition risk persists for several years, increasing dependence on successful ramp of newer brands and pipeline approvals to sustain topline.
Large M&A Timing & Near-Term EPS DragWhile strategically additive, a ~$10.9B cash acquisition heightens near-term capital outflows and integration risk, with accretion deferred many years. That long accretion horizon limits immediate earnings uplift and can pressure leverage metrics and near-term capital allocation flexibility if future approvals or market uptake disappoint.
AbbVie News
4AB FAQ
What was Abbvie’s price range in the past 12 months?
Abbvie lowest stock price was €155.20 and its highest was €207.00 in the past 12 months.
What is Abbvie’s market cap?
Abbvie’s market cap is €355.60B.
When is Abbvie’s upcoming earnings report date?
Abbvie’s upcoming earnings report date is Jul 24, 2026 which is in 31 days.
How were Abbvie’s earnings last quarter?
Abbvie released its earnings results on Apr 29, 2026. The company reported €2.319 earnings per share for the quarter, beating the consensus estimate of €2.268 by €0.051.
Is Abbvie overvalued?
According to Wall Street analysts Abbvie’s price is currently Undervalued.
Does Abbvie pay dividends?
Abbvie pays a Quarterly dividend of €1.509 which represents an annual dividend yield of 2.93%. See more information on Abbvie dividends here
What is Abbvie’s EPS estimate?
Abbvie’s EPS estimate is 3.29.
How many shares outstanding does Abbvie have?
Abbvie has 1,766,792,800 shares outstanding.
What happened to Abbvie’s price movement after its last earnings report?
Abbvie reported an EPS of €2.319 in its last earnings report, beating expectations of €2.268. Following the earnings report the stock price went up 2.827%.
Which hedge fund is a major shareholder of Abbvie?
Currently, no hedge funds are holding shares in DE:4AB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€226.01 (26.51% Upside)
€226.01 (26.51% Upside)
Blogger Sentiment
Bullish
DE:4AB Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.17%
12-Months-Change
Fundamentals
Return on Equity
68.01%
Trailing 12-Months
Asset Growth
0.22%
Trailing 12-Months
Company Description
Abbvie
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
4AB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and financial performance with multiple product growth drivers (Skyrizi, Rinvoq, neuroscience portfolio) and a raised full-year outlook. Substantial pipeline progress (regulatory submissions, combination Crohn's data, obesity signal) and major manufacturing investments reinforce long-term growth positioning. Offsets include expected HUMIRA biosimilar erosion, pressure in some oncology and aesthetic segments, selected clinical setbacks/non-differentiation and near-term acquired IPR&D expense impacts. On balance, highlights — including robust sales beats, double-digit growth for key franchises, guidance raise, and encouraging pipeline readouts — outweigh the lowlights.View all DE:4AB earnings summaries4AB Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
4AB Stock 12 Month Forecast
Average Price Target
€226.01
▲(26.51% Upside)
Technical Analysis
Options Prices
Currently, No data available
---